Natera and BGI launch new assay in China

By staff writers

June 24, 2021 -- Natera and BGI Genomics announced the launch of their BGI/Natera Signatera Assay in China for the identification of molecular residual disease (MRD).

The Signatera assay was tested in studies in nonsmall cell lung, bladder, breast, and colorectal cancers and identifies MRD up to two years earlier than standard imaging, the companies said in a release.

Natera and BGI Genomics entered a partnership in March 2019 to commercialize the Signatera test in China. Pharmaceutical companies can access the assay in China through the BGI-Natera partnership, which offers companion diagnostic registration in both China and the U.S., the companies stated.

Natera nabs ADLT status
The U.S. Centers for Medicare and Medicaid Services awarded cell-free DNA testing company Natera advanced diagnostic laboratory test (ADLT) status for...
FDA approves new uses for Natera's MRD test
The U.S. Food and Drug Administration (FDA) has granted two breakthrough device designations covering new intended uses for Natera's Signatera molecular...
Natera, Personalis team up on personalized oncology
Cell-free DNA testing company Natera and advanced genomics firm Personalis have partnered on a personalized oncology project targeted at the assessment...
Natera wins Medicare coverage for colorectal cancer test
Natera has received local coverage determination from the U.S. Centers for Medicare and Medicaid Services for serial use of the Signatera molecular residual...
Natera to collaborate with MGH on breast cancer trial
Natera plans to collaborate with Massachusetts General Hospital (MGH) on a clinical trial that will test the effectiveness of ribociclib (Kisqali) in...

Copyright © 2021

Last Updated np 9/1/2021 12:26:05 PM